⚠️Scientists report improved vision in first human trial of cellular reprogramming

An experimental therapy designed to make aging cells behave younger has shown promising early results, with two of three glaucoma patients experiencing improved vision after eight weeks.

Life Biosciences’ ER-100 uses genetic instructions for three regulatory proteins to reprogram cells and potentially repair damaged optic nerves without changing the underlying DNA sequence.

No serious adverse events were reported in the initial data, and an independent safety board recommended increasing the dose for the next patient cohort.

The findings are preliminary, with just three patients involved. But they mark an important step toward testing whether cellular reprogramming could one day treat age-related damage in humans.

@futurism 🧬